

4675 Hill Street
Cass City, MI 48726



(989) 872-2121
www.hillsanddales.com

December 13th, 2007

United States Nuclear Regulatory Commission
Region III, Office of Materials Licensing
2443 Warrenville Road
Suite 210
Lisle, IL 60532-4352

**RE: Amendment to NRC License 21-26080-02
Hills and Dales General Hospital**

Dear Sir/Madam:

The purpose of this letter is to amend our current NRC license to reflect the following changes.

Item #1 Please add the following individuals from our NRC license.

George E. Polonco, DO 35.100 and 35.200

Dr Polonco has been listed as an authorized user on the following NRC license #21-04072-01, Amendment #61. We have enclosed a copy of this license and his license to practice medicine in the state of Michigan.

Geoffrey Mayer Remes, MD 35.100 and 35.200

Dr Remes has been listed as an authorized user on the following NRC license #21-26076-01, Amendment #14. We have enclosed a copy of this license and his license to practice medicine in the state of Michigan.

Thank you for your cooperation. If you have any questions or require additional information, please contact our physicist, James Botti at 734-662-3197.

Sincerely,

A handwritten signature in black ink, appearing to read "Mike Falatko", is written over a horizontal line.

Mike Falatko
President CEO
Executive Management
Hills and Dales Hospital

RECEIVED DEC 19 2007

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES
Amendment No. 61

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Garden City Osteopathic Hospital	In accordance with letter dated December 5, 2001,
2. 6245 North Inkster Road	3. License number 21-04072-01 is amended in
Garden City, MI 48135	its entirety to read as follows:
	4. Expiration date February 28, 2005
	5. Docket No. 030-02036
	Reference No.
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400
	8. Maximum amount that licensee may possess at any one time under this license
	A. As needed
	B. As needed
	C. 1 curie
	D. As needed
9. Authorized Use:	
A. Medical use described in 10 CFR 35.100.	
B. Medical use described in 10 CFR 35.200 (excluding aerosols).	
C. Medical use described in 10 CFR 35.300.	
D. Medical use described in 10 CFR 35.400.	

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 3 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-04072-01Docket or Reference Number
030-02036

Amendment No. 61

CONDITIONS

10. Location of Use:

A. Garden City Osteopathic Hospital, 6245 Inkster Road, Garden City, Michigan

B. Cambridge Diagnostic Center, 27285 West Warren, Dearborn Heights, MI 48127 (limited to 35.100, and 35.200 material)

11. Radiation Safety Officer: Robert Hays Bixler, D.O.

12. Authorized Users:Material and Use

- A. Daniel J. Miannecki, D.O. 10 CFR 35.100, 35.200 and 35.300 (limited to phosphorous-32 for treatment of polycythemia vera, leukemia and bone metastases).
- B. Robert Hays Bixler, D.O. 10 CFR 35.100 and 35.200.
- C. Christopher Murray, D.O. 10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131).
- D. Ronald C. Lustig, D.O. 10 CFR 35.100.
- E. John R. Sutton, D.O. 10 CFR 35.300.
- F. Walter Harper, D.O. 10 CFR 35.100, 35.200, 35.300 (for treatment of hyperthyroidism and cardiac dysfunction).
- G. James P. Finch, D.O. 10 CFR 35.100 and 35.200.
- H. George E. Polonco, D.O. 10 CFR 35.100 and 35.200.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION


PAGE 3 of 3 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-04072-01Docket or Reference Number
030-02036

Amendment No. 61

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated July 19, 1994; and
- B. Letters dated January 30, 1996, January 4, 2000, and January 29, 2001 (with attachment).



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

FEB 20 2002

Date _____

By William P. Reichhold
William P. Reichhold
Materials Licensing Branch
Region III

12-10-03

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated May 9, 2003,
1. Regional Medical Imaging, P.C.	3. License number 21-26076-01 is amended in its entirety to read as follows
2. 2486 Nerredia, Suite A Flint, MI 48532	4. Expiration date June 30, 2005
	5. Docket No. 030-31367 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any, excluding xenon-133 and generators	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any, excluding iodine-131 for thyroid carcinoma	C. 1 curie

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200 (excluding xenon-133 and generators).
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).

CONDITIONS

- 10. Location of Use: 2486 Nerredia, Suite A, Flint, Michigan.
- 11. Radiation Safety Officer: Randy D. Hicks, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-26076-01Docket or Reference Number
030-31367

Amendment No. 14

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

David A. Strahle, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators), and 35.300 (excluding iodine-131 for thyroid carcinoma).
Randy D. Hicks, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators), and 35.300 (excluding iodine-131 for thyroid carcinoma).
William C. Melton, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 35.300 (excluding iodine-131 for thyroid carcinoma).
Geoffrey Mayer Remes, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 35.300 (excluding iodine-131 for thyroid carcinoma).
Jeannie Hicks, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators), 35.300 (excluding iodine-131 for thyroid carcinoma).
Miriam Pellerito, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators), 35.300 (excluding iodine-131 for thyroid carcinoma).
Chandler G. Veenhuis, D.O.	10 CFR 35.100 and 35.200 (excluding xenon-133 and generators).
Richard Small, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 35.300 (excluding iodine-131 for thyroid carcinoma).
Walter Harper, D.O.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 35.300 (excluding iodine-131 for thyroid carcinoma).


13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-26076-01Docket or Reference Number
030-31367

Amendment No.14

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application received November 1, 1994 (excluding the Quality Management Program); and
- B. Letters dated May 11, 1995 and January 4, 2001; a second letter dated January 4, 2001, and two letters dated February 23, 2001.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

JUL 29 2003

Date _____

By William P. Reichhold
William P. Reichhold
Materials Licensing Branch
Region III

FROM

POSTAGE
HERE

Returns Postage Guaranteed

X-RAY FILM
DO NOT FOLD



2443 WARRENVILLE RD

LITTLE IL 60532-3673

P: YELLOW S: 4BB I: 405

0402-8404

1Z461415031011 8542
SHIPMENT INFORMATION PAGE IS BY: 01/01/2007
78 0024 107 0-2-1 LP2004

FIRST CLASS MAIL ENCLOSED

To:

Hills & Dales HealthCare
Pharm, Non & Drugs
www.hillsdales.com

HILLS & DALES GENERAL HOSPITAL
JCAHO ACCREDITED
BRANCHING OUT... REACHING OUT

4675 HILL STREET • CASS CITY, MICHIGAN 48726

to: ^{Commissioner} United States Nuclear Regulatory
Region III office of Materials & Safety
2443 Warrenville Road, Suit 210
Little, Ill
60532-4352